Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer

BACKGROUND: Treatment with gemcitabine/nab-paclitaxel confers a survival benefit over gemcitabine monotherapy in patients with advanced pancreatic cancer (APC). However, such treatment can be associated with significant toxicities especially in older patients and carries practical disadvantages rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehman, Hasan, Chi, Jeffrey, Hakim, Nausheen, Goyal, Shreya Prasad, Olazagasti, Coral, Jose, Jyothi, Moriarty, Linda, Saif, Muhammad Wasif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692343/
https://www.ncbi.nlm.nih.gov/pubmed/33281939
http://dx.doi.org/10.1177/1756284820974912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692343/
https://www.ncbi.nlm.nih.gov/pubmed/33281939
http://dx.doi.org/10.1177/1756284820974912

Ejemplares similares